INTELLIA THERAPEUTICS, INC. Business Combination, Consideration Transferred
INTELLIA THERAPEUTICS, INC. (NTLA) reported Business Combination, Consideration Transferred of $56.11 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2024-02-22
- INTELLIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2023-12-31 was $0.00.
- INTELLIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2023-09-30 was $0.00.
- INTELLIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2023-06-30 was $0.00.
- INTELLIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2023-03-31 was $56.11M, a 0.00% change year-over-year.
- INTELLIA THERAPEUTICS, INC. business combination, consideration transferred for fiscal 2023 was $56.11M, a 0.00% change from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. business combination, consideration transferred for fiscal 2022 was $56.11M.
| Period end | Business Combination, Consideration Transferred 3 month | Business Combination, Consideration Transferred 6 month | Business Combination, Consideration Transferred 9 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $56.11M 10-K · filed 2024-02-22 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $56.11M 10-Q · filed 2023-11-09 | $56.11M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $56.11M 10-Q · filed 2023-08-03 | $56.11M derived: sum of 3 quarters · filed 2023-08-03 | $56.11M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $56.11M 10-Q · filed 2023-05-04 | $56.11M derived: sum of 2 quarters · filed 2023-05-04 | $56.11M derived: sum of 3 quarters · filed 2023-05-04 | $56.11M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $56.11M 10-K · filed 2023-02-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $56.11M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $56.11M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $56.11M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |